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Long-term population-representative data on motor fluctuations (MF) and levodopa-induced 
dyskinesias (LID) in Parkinson’s disease (PD) is lacking.  
 
Methods 
The CamPaIGN cohort comprises incident PD cases followed for up to 13 years (n=141). 
Cumulative incidence of MF and LID and risk factors were assessed using Kaplan-Meyer and 
Cox regression analyses. 
 
Results 
Cumulative incidences of MF and LID were 54.3% and 14.5% at 5 years and 100% and 55.7% 
at 10 years, respectively. Higher baseline UPDRS-total and SNCA rs356219(A) predicted MF, 
while higher baseline MMSE and GBA mutations predicted LID. Early levodopa use did not 
predict motor complications. Both early MF and LID predicted reduced mortality in older 
patients (age at diagnosis > 70). 
 
Conclusion 
Our data support the hypothesis that motor complications are related to severity of nigrostriatal 
pathology rather than early levodopa use, and indicate that early motor complications do not 
necessarily confer a negative prognosis.   
  
Introduction 
After a variable period of dopaminergic treatment, Parkinson’s disease (PD) patients develop 
levodopa-induced motor complications including motor fluctuations (MF) and levodopa-
induced dyskinesias (LID), with important implications for quality of life. Understanding 
which patients are at high risk for these complications would be of benefit in terms of 
prognostication and planning management.  
 
The natural history and risk factors for MF and LID are still incompletely understood. Current 
knowledge is mostly derived from cross-sectional studies or clinical trials on highly selected 
patient groups,1-6 not representative of PD in the population. To overcome this, some studies 
have employed population-based PD cohorts,7-11 but only two have described the incidence and 
risk factors for MF and LID in a prospective manner, and follow-up was limited to 5 years.9, 10  
 
The Cambridgeshire Parkinson’s Incidence from GP to Neurologist (CamPaIGN) cohort is an 
unbiased incident population-based PD cohort, comprising newly-diagnosed cases recruited 
within the county of Cambridgeshire, UK, between December 2000 and December 2002.12 
This study was established to provide comprehensive and true-to-life data on the natural history 
of idiopathic PD in terms of both motor symptoms and non-motor symptoms. Baseline data 
and follow-up data at 3.5, 5, 7, and 10 years from diagnosis have been published previously,12-
16 and shown that there is not only motor but also cognitive heterogeneity in PD and that 
baseline clinical and genetic variables are predictive of prognosis. Now, follow-up data to 13 
years are available.  
 
Using data from this well-characterized cohort, we analysed incidence of MF and LID and their 
baseline clinical and genetic risk factors, which, to our knowledge, has not been explored in 
population-based cohorts followed for more than 10 years. In addition, we examined for the 




Subjects were from the CamPaIGN cohort.12 Idiopathic PD was diagnosed using UKPDS Brain 
Bank criteria. All cases were followed-up at approximately 2-yearly intervals. At the 3-4 year 
timepoint, diagnostic re-evaluation was undertaken with repeated application of UKPDSBB 
criteria to maximise diagnostic accuracy.14 Of 142 patients included in the last published 
analysis at 10 year,16 one was excluded due to a change in diagnosis (essential tremor and 
osteoarthritis), thus 141 were included in this study. The study protocol was approved by the 
local ethics committee and written informed consent was obtained from all subjects. 
 
Assessments 
At baseline and follow-up, patients underwent detailed clinical and neuropsychological tests as 
previously reported.15 Disease severity was evaluated using the Unified Parkinson’s Disease 
Rating Scale (UPDRS) and Hoehn and Yahr (HY) scale. Presence of MF and LID was assessed 
using the UPDRS section 4. Dementia was diagnosed according to DSM-IV criteria in patients 
with Mini-mental State Examination (MMSE) ≤24. 
 
Genotyping was performed for candidate genes with potential prognostic significance 
including: MAPT H1 versus H2 haplotype, SNCA rs356219, APOE ε-2/3/4 alleles, COMT 
val(158)met, BDNF val(66)met, and GBA sequencing for pathogenic variants.16-19  
 
Statistical Analysis 
Time of PD diagnosis was defined as t=0. Cumulative incidence of MF and LID was calculated 
using Kaplan-Meier survival analysis. Times of onset of MF, LID, and dementia were 
calculated as the midpoint of the interval between the assessment at which the outcome was 
first recorded and the preceding assessment.  
 
Cox regression analysis was used to investigate covariates which might influence development 
of MF and LID. All demographic, clinical, and genetic covariates putatively relevant to 
outcome were evaluated using univariate analyses (Table1). Multivariate analysis was then 
performed using covariates with an unadjusted p value ≤0.1 and a backward stepwise approach. 
Influence of MF and LID on mortality and risk of dementia was analyzed using similar 
univariate and multivariate Cox regression analyses with MF and LID as time-dependent 
covariates. Statistical analyses were performed using IBM SPSS version 22 or SAS. 
 
Results 
Patients were followed up for a maximum of 13 years. Mean follow-up duration was 7.8 ± 3.5 
years. Mean age at diagnosis was 70.2 ± 9.6 years. All patients received dopaminergic therapy 
during the course of follow-up. Sixty-nine were receiving treatment at baseline, of whom 42 
were receiving levodopa. No patients had undergone deep brain stimulation or were receiving 
continuous infusion therapies during the follow-up period,  
Risk factors for MF and LID 
Eighty-three patients developed MF, with a cumulative incidence of 54.3% and 100% at 5 and 
10 years, respectively. Median time to MF was 4.7 years (Figure 1). The multivariate model 
revealed that higher baseline UPDRS-total and the SNCA rs356219 A allele were independently 
associated with increased risk of MF (Table 1). 
 
LID developed in 39 patients, with a cumulative incidence of 14.5% and 55.7% at 5 and 10 
years, respectively. Median time to LID was 8.7 years (Figure 1). Multivariate analysis showed 
that higher MMSE at baseline and carrying a GBA mutation were independently associated 
with increased risk of LID (Table 1). 
 
MF and LID as prognostic factors 
In univariate analyses, both MF and LID were independently associated with reduced mortality 
(unadjusted HR 0.239, 95% CI 0.133-0.430, p<0.001 for MF; unadjusted HR 0.355, 95% CI 
0.186-0.676, p=0.002 for LID). Multivariate analysis adjusting for covariates independently 
associated with mortality (diagnosis age, UPDRS-total, baseline levodopa use, smoking) 
showed similar results (adjusted HR 0.259, 95% CI 0.136-0.493, p<0.001 for MF; adjusted HR 
0.426, 95% CI 0.210-0.865, p=0.018 for LID). Stratification by age at diagnosis revealed  
associations with lower mortality reached significance only in patients over the cohort median 
of 70 (unadjusted HR 0.225, 95% CI 0.114-0.442, p<0.001 for MF; unadjusted HR 0.296, 95% 
CI 0.121-0.724, p=0.008 for LID). Neither MF nor LID were associated with risk of dementia.  
 
Discussion  
This long-term study in an incident, population-based cohort provides ‘real world’ data for the 
frequency of motor complications in a typical PD population throughout the course of their 
disease, and indicates that at 10 years virtually all surviving patients with PD have developed 
MF whereas only 56% experience LID.  
 
Previous population-based prospective cohort studies have only provided data to 5 years .9, 10 
The cumulative incidence of MF at 5 years was higher at 54.3% in our study compared with 
those studies showing 43% and 23%, respectively, which may reflect differences in the 
population, treatment approaches and data collection methods. Our high incidence of MF at 5 
years appears at odds with the classical view that MF is associated with advanced PD. However, 
studies have shown that MF can occur as early as 6 months from levodopa initiation,2, 20 and 
one study showed that 25% of patients initially treated with dopaminergic agonists and 43% of 
patients initially treated with levodopa developed MF in 2 years.21 At 10 years, the cumulative 
incidence of MF was 100% in our cohort. The Sydney Multicentre Study22 similarly reported 
that all surviving patients had MF at 20 years, supporting our finding that virtually all patients 
eventually develop MF. An important clinical implication of this is that almost all patients still 
benefit from dopaminergic treatment in the long-term, as evidenced by the presence of MF, and 
this should be considered when adjusting medications. However, it remains possible that there 
is a subgroup who do not benefit from levodopa but are censored from analysis at an earlier 
stage due to death or withdrawal. 
 
It has previously been reported that up to 80% of patients develop LID within 5 years of 
diagnosis, and 80-90% of patients experience LID after 10 years, 1, 3, 23 but these estimates 
come from studies of selected cohorts. The older average age of our cohort may be relevant, as 
patients with a younger age at onset are more likely to develop LID.10, 24, 25 Our 10-year data 
are comparable to data from previous retrospective community-based studies with a similar 
age at onset 7, 8, reporting that 53-59% had LID at 10 or more years. However, the reason for 
the low cumulative incidence (14.5%) of LID at 5 years, when compared with previously 
mentioned population-based prospective cohort studies with a similar age at onset (cumulative 
incidence at 5 years 24% and 30% respectively9, 10), is not clear.   
 
In agreement with other studies,5, 9 our data show MF are associated with increased baseline 
disease severity, but in contrast with some previous reports,2, 5, 7 we did not find an association 
with levodopa use at baseline or levodopa-equivalent daily dose (LEDD)26 in the multivariate 
analysis. This indicates that early levodopa is not a major factor in driving earlier motor 
complications, in keeping with studies comparing motor complications in subgroups of patients 
with differing baseline treatment approaches (levodopa versus dopamine agonists versus no 
treatment).27 This supports the general shift in opinion favouring earlier rather than delayed 
onset of levodopa treatment.28  
 
Higher MMSE at baseline was associated with earlier LID in multivariate analysis, which is a 
novel finding, but previous studies have not specifically examined the relationship between 
cognition and LID to our knowledge. A plausible explanation for this finding is that patients 
developing early LID represent a subgroup of highly levodopa-responsive patients in whom 
pathology is relatively confined to the nigrostriatal system, with minimal extrastriatal and 
cortical involvement. The observation that LID and MF are not associated with earlier dementia 
(despite association with disease severity) provides further support for this hypothesis. 
However it also is possible that this observation could be influenced by a tendency to use lower 
medication doses in individuals with cognitive impairment. 
 
Association of the SNCA rs356219 A allele and MF is an unexpected finding because this 
variant has been associated with reduced PD susceptibility and older age at onset29-31 as well 
as reduced plasma alpha-synuclein levels in PD.32 Our observed association may reflect less 
severe diffuse alpha-synuclein pathology in levodopa-responsive patients who develop early 
MF, but it is a finding which requires further replication in an independent cohort.  
 
We observed an increased LID risk in GBA mutation carriers, in line with reports that GBA 
mutations are associated with more rapid motor progression19, 33 earlier age of onset33-35, and 
possibly earlier DBS surgery.36 GBA-PD is also generally associated with rapid cognitive 
decline and earlier dementia19, 33, 34, whereas we found higher baseline MMSE also increased 
LID risk. However, longitudinal studies have shown that GBA status does not determine 
cognitive status at baseline,19, 34, 35 and we propose that the GBA association with LID is driven 
by the more aggressive pathology that tends to characterize this condition.  
 
Another novel finding is that MF and LID were associated with reduced mortality in patients 
>70 at diagnosis, suggesting that levodopa-responsiveness predicts better prognosis in older 
patients. Levodopa-responsive symptoms are associated with presynaptic nigrostriatal 
dopaminergic loss,37, 38 whereas mortality in advanced disease likely results from pathology 
outside the nigrostriatal system.16 This suggests that severity of motor dysfunction at baseline 
is not necessarily a poor prognostic feature, if the motor deficits are treatment-responsive.  
 
In conclusion, our findings are in keeping with the idea that timing of motor complications 
reflects severity of pathology in the dopaminergic nigrostriatal system rather than levodopa use 
at baseline.39 We propose that idiopathic PD patients are on a spectrum from those with disease 
predominantly confined to the nigrostriatal system, with more prominent motor symptoms at 
baseline and earlier motor complications but generally preserved cognition and prolonged 
survival; to those with diffuse alpha-synuclein pathology with less treatment-responsiveness 
and less motor complications but more cognitive impairment and reduced survival. Future work 
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Figure Legend 
Figure 1. Kaplan-Meier plots of survival to onset of motor fluctuations (MF) and levodopa-
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